Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oregon for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oregon only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oregon (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Keith Goldstein (NPI 1861462566)

Field	Value
Entity Type	Individual
Organization	Keith Goldstein
Address	520 Country Club
City	Eugene
State	OR
ZIP	97401
Taxonomy	Medical Oncology Physician
NPI Enumerated	January 25, 2006

Payer Source	Total Paid
Medicare	$1M
Medicaid	$0

Key Findings

This provider's Medicare footprint is modest in absolute scale: Total Medicare revenue: $1M while Total Medicaid revenue: none (no Medicaid billing on file), making the practice effectively single‑payer with Medicare driving all reported public-payer revenue. The absence of Medicaid billing is a clear structural characteristic of this profile rather than a minor gap in the data.

Revenue is highly concentrated in a small set of injectable oncology drugs: top 3 Medicare codes by revenue account for 91.0% of this provider's total Medicare revenue, led by J9271 ($549.4K, 54.1%) and J9144 ($348.8K, 34.4%) with 99213 contributing $25.8K (2.5%). This concentration shows the practice’s economics are dominated by high-cost biologic/immunotherapy administrations rather than routine office visit reimbursement.

The code mix and descriptions indicate an infusion‑centric medical oncology practice: J9271 (pembrolizumab) and J9144 (daratumumab) are antineoplastic injectables that together make up the majority of Medicare revenue, while chemotherapy administration codes such as 96413 and infusion management codes (96375, 96365) appear but account for much smaller revenue shares. This pattern is consistent with a practice focused on administering high-cost specialty drugs in an outpatient infusion setting rather than a general primary‑care model.

Competitive standing for the top drug codes is moderate nationally: J9271 ranks #806 of 1841 providers (55th percentile; typical, unremarkable volume for this code) and J9144 ranks #252 of 615 providers (57th percentile; typical, unremarkable volume for this code), indicating neither regional dominance nor an outlier specialty center for these specific agents. In short, the provider participates in commonly billed oncology injectables at volumes that are around the middle of national peers rather than at the top.

Office E/M activity is visible but small relative to drug revenue: 99213 accounts for $25.8K and 403 claims and ranks #38580 of 457151 providers (92th percentile; typical, unremarkable volume for this code), suggesting that while routine established‑patient visits are billed at a higher-than‑typical percentile relative to the broad provider pool, they are a minor contributor to overall Medicare dollars. This supports an operational model where clinical management accompanies infusion services but does not drive practice revenue.

The provider has a long NPI tenure—NPI enumerated (registered): 2006-01-25 (~20 years ago)—which suggests an established practice history in the market and likely continuity in referral and treatment patterns that produced the current Medicare billing mix. Long tenure combined with an infusion-centric code profile is consistent with a sustained oncology practice rather than a new entrant with transient billing patterns.

Being effectively single‑payer with Medicare as the sole reported public payer and a heavy revenue concentration in two injectable agents creates both operational clarity and payer concentration risk: reliance on J9271 and J9144 (together 88.5% of Medicare revenue by the listed shares) ties practice revenue to utilization and reimbursement policies for those agents. Analysts should note the lack of Medicaid billing (none (no Medicaid billing on file)) when assessing payer diversification, network leverage, and potential sensitivity to changes in Medicare drug payment rules.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

36 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,400	$40	$549.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,180	$40	$348.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	400	$60	$25.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	220	$100	$21.8K
J1439	Injection, ferric carboxymaltose, 1 mg	12,750	$1	$12.8K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	120	$60	$6.8K
J0185	Injection, aprepitant, 1 mg	5,980	$1	$6K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	50	$100	$4.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	60	$90	$4.7K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	40	$90	$3.2K

Showing 1–10 of 36

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 36 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oregon Distribution

Keith Goldstein — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oregon

Full comparison — all codes billed, vs. state median

36 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	30	8,700	$40	$430.9K
J9144	2	10	9,180	$40	$343.4K
J3490	39	50	40	$640	$42.9K
J1439	12	10	19,130	$1	$20.1K
96413	27	90	150	$100	$18.2K
99214	3,788	6,070	80	$70	$10.3K
99233	940	1,310	70	$90	$9.1K
J0185	6	20	5,140	$1	$7.2K
96365	64	110	70	$50	$5.8K
99213	214	5,480	60	$50	$5.7K

Showing 1–10 of 36

Related Providers

Other providers that share a Tax Identification Number (TIN) with Keith Goldstein, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Oncology Associates Of Oregon P C	OR	Hematology & Oncology Physician	$0	$2M
Michael Monticelli	CO	Hematology & Oncology Physician	$1.3M	$0
Bo Wang	OR	Hematology & Oncology Physician	$1.1M	$0
Marc Uemura	OR	Internal Medicine Physician	$1M	$0
Jeff Sharman	OR	Medical Oncology Physician	$878.7K	$0
Benjamin Cho	OR	Medical Oncology Physician	$816K	$0
John Fitzharris	OR	Medical Oncology Physician	$672.6K	$0
Miho Dougherty	OR	Hematology & Oncology Physician	$633.2K	$0
Christopher Yasenchak	OR	Hematology & Oncology Physician	$604.5K	$0
Jonathan Gross	OR	Medical Oncology Physician	$533.5K	$0

Nearby Providers

Other providers in the same ZIP code as Keith Goldstein, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Peacehealth Medical Group	OR	Family Medicine Physician	$0	$45.3M
Options Counseling Services Of Oregon	OR	Mental Health Counselor	$0	$25.9M
Eugene Emergency Physicians PC	OR	Emergency Medicine Physician	$0	$16.9M
Center For Family Development, Inc.	OR	Mental Health Counselor	$0	$15.6M
Laurel Hill Center	OR	Eyewear Supplier	$0	$14M
Looking Glass Community Services	OR	Mental Health Counselor	$0	$13.5M
Peacehealth	OR	General Acute Care Hospital	$0	$13.3M
Addiction Counseling And Education Services Inc.	OR	Mental Health Counselor	$0	$12.8M
Oregon Eye Consultants LLC	OR	Ophthalmology Physician	$0	$9.6M
Ch Mh Services (or), LLC	OR	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$9.4M

Keith Goldstein — Billing Profile & Reimbursement Data

Sign up for Keith Goldstein — Billing Profile & Reimbursement Data policy alerts

Keith Goldstein — Billing Profile & Reimbursement Data

Sign up for Keith Goldstein — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References